Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amyvid PET imaging for predicting cognitive decline in AD and MCI
NCT00857506Phase 2Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Jan 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of florbetapir (18F) in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 36 months. Started Jan 2009; status: completed.
02
Drugs
florbetapir (18F)
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00857506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857506.